Harmony Biosciences Holdings (HRMY) Net Cash Flow (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Net Cash Flow data on file, last reported at -$163.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 553.1% year-over-year to -$163.1 million; the trailing twelve-month figure through Mar 2026 stood at $100.4 million (down 35.65% YoY), and the FY2025 full-year result was $299.5 million, up 111.9% from the prior year.
• Net Cash Flow fell to -$163.1 million in Q1 2026, from $105.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $105.5 million in Q4 2025 to a low of -$163.1 million in Q1 2026.
• A 5-year average of $20.9 million and a median of $24.8 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 874.83% in 2024 and tumbled 553.1% in 2026, its largest moves.
• Tracing HRMY's Net Cash Flow over 5 years: stood at -$17.6 million in 2022, then advanced by 26.4% to -$12.9 million in 2023, then soared by 607.89% to $65.6 million in 2024, then surged by 60.74% to $105.5 million in 2025, then tumbled by 254.6% to -$163.1 million in 2026.
• Business Quant data shows HRMY's Net Cash Flow at -$163.1 million in Q1 2026, $105.5 million in Q4 2025, and $100.9 million in Q3 2025.